Home > Gastroenterology > ECCO 2022 > Novel Treatment Modalities > Guselkumab plus golimumab promising combination for ulcerative colitis

Guselkumab plus golimumab promising combination for ulcerative colitis

Presented By
Prof. Bruce Sands, Mount Sinai School of Medicine, NY, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECCO 2022
Trial
Phase 2, VEGA
The combination of guselkumab and golimumab resulted in improved clinical outcomes in participants with active ulcerative colitis (UC) compared with either guselkumab or golimumab monotherapy in a phase 2 study. Moreover, the safety profiles were similar across treatment groups. Further trials are warranted to evaluate the safety and efficacy of this promising combination regimen in patients with UC. Preclinical data from a murine model of acute colitis has suggested that the combination therapy of guselkumab, an IL-23 inhibitor, and golimumab, a TNF inhibitor, may lead to improved outcomes in patients with UC [1]. A phase 2, proof-of-concept study (NCT03662542) was conducted to assess the efficacy and safety of guselkumab plus golimumab compared with guselkumab or golimumab monotherapy in participants with moderately to severely active UC [2]. Participan...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on